Bio-Rad Laboratories, Inc. financials

  1. Home
  2. Financials
  3. BIO
BIO CIK 0000012208

Source: EDGAR filings · Built 2026-06-02T02:28:53Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 374.30M 289.00M 217.80M 81.20M 535.22M 475.61M
EBITDA 212.60M 420.60M 483.70M 619.90M 637.94M 559.93M
Working Capital 2.39B 2.56B 2.53B 2.59B 1.31B 1.51B
Net Debt 862.00M 895.00M 1.02B 953.42M 152.52M -436.50M
Gross Margin 51.87% 53.73% 53.42% 55.93% 56.05% 56.49%
Operating Margin 1.83% 10.48% 12.65% 17.22% 17.12% 16.55%
Net Margin 29.42% -71.86% -23.86% -129.45% 145.57% 149.84%
Return on Equity (ROE) 10.20% -28.07% -7.29% -37.73% 31.09% 38.57%
Return on Assets (ROA) 7.18% -19.69% -5.18% -26.87% 23.90% 29.40%
Current Ratio 5.62× 6.48× 5.83× 5.55× 2.92× 3.39×
Debt-to-Equity 0.19× 0.21× 0.16× 0.14× 0.05× 0.02×
Effective Tax Rate 23.67% 21.27% 25.03% 22.89% 21.93% 22.44%
Cash Conversion Ratio 0.70× -0.25× -0.59× -0.05× 0.16× 0.15×
Accruals Ratio 0.02× -0.25× -0.08× -0.28× 0.20× 0.25×
SBC % of Revenue 2.25% 2.43% 2.29% 2.17% 1.75% 1.63%
CapEx Coverage 3.37× 2.74× 2.39× 1.72× 4.99× 5.35×
Free Cash Flow Per Share $13.72 $10.24 $7.46 $2.73 $17.72 $15.77

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 10.88× — — — 5.37× 4.61×
P/FCF 22.08× 32.07× 43.30× 154.24× 42.64× 36.97×
FCF Yield 4.53% 3.12% 2.31% 0.65% 2.35% 2.71%
EV / EBITDA 42.93× 24.16× 21.61× 21.74× 36.02× 30.62×
P/S 3.20× 3.61× 3.53× 4.47× 7.81× 6.91×
P/B 1.11× 1.41× 1.08× 1.30× 1.67× 1.78×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 2.58B 2.57B 2.67B 2.80B 2.92B 2.55B
Cost of Goods and Services Sold 1.24B 1.19B 1.24B 1.23B 1.28B 1.11B
Gross Profit 1.34B 1.38B 1.43B 1.57B 1.64B 1.44B
Research and Development Expense 275.60M 295.90M 247.40M 256.90M 260.64M 217.76M
Selling, General and Administrative Expense 844.30M 814.00M 841.70M 827.80M 877.12M 798.80M
Operating Income (Loss) 47.20M 269.00M 337.80M 482.60M 500.34M 421.33M
Income Tax Expense (Benefit) 235.60M -498.30M -212.80M -1.08B 1.19B 1.10B
Net Income (Loss) Attributable to Parent 759.90M -1.84B -637.30M -3.63B 4.25B 3.81B
Earnings Per Share, Basic $27.87 $-65.36 $-21.82 $-121.79 $142.61 $128.13
Weighted Average Number of Shares Outstanding, Basic 27.26M 28.21M 29.21M 29.79M 29.83M 29.77M
Earnings Per Share, Diluted $27.85 $-65.36 $-21.82 $-121.79 $140.83 $126.47
Weighted Average Number of Shares Outstanding, Diluted 27.28M 28.21M 29.21M 29.79M 30.21M 30.16M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 529.80M 488.10M 403.80M 434.20M 470.78M 662.21M
Assets, Current 2.91B 3.03B 3.05B 3.16B 1.99B 2.14B
Assets 10.58B 9.36B 12.30B 13.50B 17.80B 12.97B
Long-term Debt 1.20B 1.20B 1.21B — — —
Liabilities, Current 517.00M 467.80M 522.80M 568.71M 680.94M 631.54M
Long-term Debt, Excluding Current Maturities 1.20B 1.20B 1.20B 1.20B 10.51M 12.26M
Liabilities 3.12B 2.79B 3.56B 3.89B 4.11B 3.09B
Stockholders' Equity Attributable to Parent 7.45B 6.57B 8.74B 9.62B 13.69B 9.89B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 532.20M 455.20M 374.90M 194.40M 669.46M 584.97M
Payments to Acquire Property, Plant, and Equipment 157.60M 165.60M 156.70M 112.80M 133.75M 108.56M
Net Cash Provided by (Used in) Investing Activities -189.70M -160.20M 20.20M -1.21B -797.38M -69.89M
Payments for Repurchase of Common Stock 295.50M 203.60M 428.70M 215.70M 50.00M 100.00M
Net Cash Provided by (Used in) Financing Activities -283.20M -218.80M -425.60M 973.60M -55.43M -523.04M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (BIO CIK 0000012208), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

VKTX

VIKING THERAPEUTICS, INC.

DNOW

DNOW INC.

NB

NioCorp Developments Ltd.